Conventional Therapy of Sjogren's Syndrome

Overview

Journal Clin Rev Allergy Immunol

Specialty Allergy & Immunology

Date 2007 Nov 10

PMID 17992595

Citations 24

Authors

Clio P Mavragani

Haralampos M Moutsopoulos

Affiliations

Soon will be listed here.

Abstract

Sjogren's syndrome (SS) is a chronic autoimmune disorder affecting mainly middle-aged women. It is characterized by lymphocytic infiltration and destruction of the exocrine glands (mainly the salivary and lacrimal glands), resulting in dry mouth and eyes. Symptoms of SS are chronic and sometimes devastating, compromising the quality of life at a major extent. Despite its autoimmune nature, evidence for the use of immunosuppressive agents, which are the mainstay of therapy of diseases of autoimmune origin, is limited. Keratoconjunctivitis sicca (KCS), the main ocular manifestation of SS, is managed with tear substitutes, as well as local and systemic stimulators of tear secretion and supportive surgical procedures. Management of oral manifestations includes intense oral hygiene, prevention and treatment of oral infections, use of saliva substitutes, and local and systematic stimulation of salivary secretion. Cholinergic agents, such as pilocarpine and cevimeline are the cornerstone of current therapy in SS. Corticosteroids, cyclophoshamide, and nucleoside analogues are reserved for severe extraglandular manifestations of SS. The role of anti-B-cell therapy is a promising option for glandular and extraglandular manifestations of the disease, as well as for the management of SS-associated lymphoma.

Citing Articles

Altered characteristics of regulatory T cells in target tissues of Sjögren's syndrome in murine models.

Zhou J, Felix F, Jiang Y, Li D, Kim M, Jang D Mol Immunol. 2024; 174:47-56.

PMID: 39197397 PMC: 11500054. DOI: 10.1016/j.molimm.2024.08.003.

Five new secondary metabolites from an endophytic fungus sp. SZSJ-7B.

Chen Y, Wang H, Ke X, Sang Z, Kuang M, Peng W Front Plant Sci. 2022; 13:1049015.

PMID: 36452113 PMC: 9702824. DOI: 10.3389/fpls.2022.1049015.

Inhibition of NLRP3 inflammasome activity by MCC950 leads to exacerbation of Sjӧgren's syndrome pathologies in non-obese diabetic mice.

Zhou J, Onodera S, Yu Q Immunology. 2022; 168(4):697-708.

PMID: 36353754 PMC: 10038882. DOI: 10.1111/imm.13605.

Neuro-Sjögren: Uncommon or underestimated problem?.

Jaskolska M, Chylinska M, Masiak A, Sieminski M, Zietkiewicz M, Czuszynska Z Brain Behav. 2020; 10(8):e01665.

PMID: 32583978 PMC: 7428478. DOI: 10.1002/brb3.1665.

Targeted Proteomics Guided by Label-free Quantitative Proteome Analysis in Saliva Reveal Transition Signatures from Health to Periodontal Disease.

Bostanci N, Selevsek N, Wolski W, Grossmann J, Bao K, Wahlander A Mol Cell Proteomics. 2018; 17(7):1392-1409.

PMID: 29610270 PMC: 6030726. DOI: 10.1074/mcp.RA118.000718.

References

Ramos-Casals M, Lopez-Guillermo A, Brito-Zeron P, Cervera R, Font J . Treatment of B-cell lymphoma with rituximab in two patients with Sjögren's syndrome associated with hepatitis C virus infection. Lupus. 2005; 13(12):969-71. DOI: 10.1191/0961203304lu2049xx. View

Linardaki G, Moutsopoulos H . The uncertain role of immunosuppressive agents in Sjögren's syndrome. Cleve Clin J Med. 1998; 64(10):523-6. DOI: 10.3949/ccjm.64.10.523. View

Somer B, Tsai D, Downs L, Weinstein B, Schuster S . Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum. 2003; 49(3):394-8. DOI: 10.1002/art.11109. View

Pedersen A, Bardow A, Nauntofte B . Salivary changes and dental caries as potential oral markers of autoimmune salivary gland dysfunction in primary Sjogren's syndrome. BMC Clin Pathol. 2005; 5(1):4. PMC: 554998. DOI: 10.1186/1472-6890-5-4. View

Levy Y, Uziel Y, Zandman G, Rotman P, Amital H, Sherer Y . Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. Ann N Y Acad Sci. 2005; 1051:779-86. DOI: 10.1196/annals.1361.121. View

Skopouli F, Talal A, Galanopoulou V, Tsampoulas C, Drosos A, Moutsopoulos H . Raynaud's phenomenon in primary Sjögren's syndrome. J Rheumatol. 1990; 17(5):618-20. View

Fife R, Chase W, Dore R, Wiesenhutter C, Lockhart P, Tindall E . Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. Arch Intern Med. 2002; 162(11):1293-300. DOI: 10.1001/archinte.162.11.1293. View

ter Borg E, Haanen H, Haas F, Bistervels J, Huisman F, Kerckhaert J . Treatment of primary Sjögren's syndrome with D-penicillamine: a pilot study. Neth J Med. 2003; 60(10):402-6. View

Porter S, Scully C, Hegarty A . An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004; 97(1):28-46. DOI: 10.1016/j.tripleo.2003.07.010. View

10.

Voulgarelis M, Giannouli S, Anagnostou D, Tzioufas A . Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas. Rheumatology (Oxford). 2004; 43(8):1050-3. DOI: 10.1093/rheumatology/keh248. View

11.

Ramos-Casals M, Anaya J, Garcia-Carrasco M, Rosas J, Bove A, Claver G . Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore). 2004; 83(2):96-106. DOI: 10.1097/01.md.0000119465.24818.98. View

12.

Skopouli F, Barbatis C, Moutsopoulos H . Liver involvement in primary Sjögren's syndrome. Br J Rheumatol. 1994; 33(8):745-8. DOI: 10.1093/rheumatology/33.8.745. View

13.

Petrone D, Condemi J, Fife R, Gluck O, Cohen S, Dalgin P . A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 2002; 46(3):748-54. DOI: 10.1002/art.510. View

14.

Goules A, Masouridi S, Tzioufas A, Ioannidis J, Skopouli F, Moutsopoulos H . Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome. Medicine (Baltimore). 2000; 79(4):241-9. DOI: 10.1097/00005792-200007000-00005. View

15.

Pillemer S, Leakan R, Sankar V, Manny J, Baum B, Smith J . Prominent adverse effects of thalidomide in primary Sjögren's syndrome. Arthritis Rheum. 2004; 51(3):505-6. DOI: 10.1002/art.20416. View

16.

Pijpe J, van Imhoff G, Vissink A, van der Wal J, Kluin P, Spijkervet F . Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Ann Rheum Dis. 2004; 64(6):958-60. PMC: 1755505. DOI: 10.1136/ard.2004.030684. View

17.

Soliotis F, Mavragani C, Moutsopoulos H . Central nervous system involvement in Sjogren's syndrome. Ann Rheum Dis. 2004; 63(6):616-20. PMC: 1755013. DOI: 10.1136/ard.2003.019497. View

18.

Gottenberg J, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A . Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2004; 64(6):913-20. PMC: 1755517. DOI: 10.1136/ard.2004.029694. View

19.

De Seze J, Delalande S, Fauchais A, Hachulla E, Stojkovic T, Ferriby D . Myelopathies secondary to Sjögren's syndrome: treatment with monthly intravenous cyclophosphamide associated with corticosteroids. J Rheumatol. 2006; 33(4):709-11. View

20.

Fox P, Datiles M, Atkinson J, Macynski A, Scott J, Fletcher D . Prednisone and piroxicam for treatment of primary Sjögren's syndrome. Clin Exp Rheumatol. 1993; 11(2):149-56. View